Clinical Trial Update: Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease [Phase 3]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 3 study evaluating cyclophosphamide for systemic sclerosis-associated interstitial lung disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Systemic Sclerosis, Scleroderma | Phase 3 | Status: COMPLETED